Does molnupiravir pose a cancer risk?

There is insufficient scientific data or clinical studies to show that Molnupiravir capsules (Molnupiravir) significantly increases the risk of cancer. Monoravir is a new antiviral drug mainly used to treat COVID-19. During the drug development and approval process, the safety of a drug is often evaluated extensively, including consideration of potential cancer risks.

To be clear, however, the long-term safety of any new drug requires long-term monitoring and studies in a broad population to assess potential adverse effects, including cancer risk. Therefore, the medical community and regulatory agencies will continue to monitor and evaluate monogravir capsules or other new drugs.

In addition, the dosage and treatment time of monogravir capsules are usually determined according to the doctor's prescription. Patients should use the drug strictly in accordance with the doctor's recommendations, pay close attention to any discomfort or unusual experience during use, and report to the doctor in time.

In short, based on current scientific knowledge and research results, there is insufficient evidence that monogravir capsules will significantly increase the risk of cancer. However, the safety and long-term effects of drugs are still being continuously studied and evaluated, so patients should follow their doctors' recommendations when using drugs and pay close attention to relevant health information and research developments. If you have any concerns or concerns about your medicines, you should seek prompt advice from a medical professional.

Monolavir capsules are already on the market in China, but are not yet included in medical insurance. Please consult your local hospital pharmacy for specific prices. The cheaper ones abroad are Indian generic drugs, which cost around three to four hundred yuan, and the ingredients of domestic original drugs and foreign generic drugs are basically the same.